2018 ASCO Annual Meeting

Robert M. Jotte, MD, PhD, Rocky Mountain Cancer Centers, presenting Abstract 9000, IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel vs Carboplatin + nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC, during Saturday Press Briefing

Chicago, IL - 2018 ASCO Annual Meeting - Robert M. Jotte, MD, PhD, Rocky Mountain Cancer Centers, presenting Abstract 9000, IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel vs Carboplatin + nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC, during Saturday Press Briefing at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Saturday June 2, 2018. Approximately 40,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 54th Annual Meeting, which is being held at McCormick Place. The ASCO Annual Meeting highlights the latest findings in all major areas of oncology, from basic to clinical and epidemiological studies. Photo by © ASCO/Brian Powers 2018 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org